Abstract 1498P
Background
Acute myeloid leukemia (AML) is a fatal cancer in patients over 65 years old, with a five-year relative survival rate of 10.8%. There is no literature regarding specific determinants of palliative care (PC) utilization in this population. We studied trends and determinants in PC utilization among hospitalized patients using the National Inpatient Sample (NIS).
Methods
This is a retrospective study using NIS data from 2016 to 2020. We included patients aged 65 years or older who were admitted with AML. We identified patients who had an encounter with PC during their hospitalization. The cohort was divided between patients with an encounter with PC and those without. Baseline characteristics were identified and compared between the two groups. Total charges (TC) during hospitalization were measured as an outcome, and then multivariate logistic regression analysis was performed to adjust for confounders.
Results
There were 44,375 patients over 65 years old admitted with AML. Of those, 22% had an encounter with PC. Baseline characteristics and differences between those in which PC was consulted and those in which they were not consulted are depicted in the table. Significant differences were observed in patients who had an encounter with PC, such as higher utilization in the White race (78% vs. 75%). They had higher rates of Heart Failure (HF) (23% vs 17%, p<0.001), acute kidney injury (AKI) (44% vs. 30%, p<0.001), and chronic kidney disease (CKD) (15% vs 12%, p 0.0018) than patients who did not have an encounter with PC. Type of insurance and hospital bed size were not significantly associated with PC utilization. Significantly, PC was consulted less in hospitals in the south region. While adjusting for other confounders, in the multivariate regression analysis, encounters with PC were associated with a decrease in TC during hospitalization of $ 49,047 (p<0.001).
Conclusions
Overall, PC utilization was low. It was reduced in hospitals located in the south region of the USA. It was higher in patients of the White Race and in patients with HF, AKI, and CKD and was associated with decreased cost burden. Our results highlight the need for early palliative care involvement in patients with AML in hospital settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10